TORL Biotherapeutics LLC
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2024 | $158 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
TORL Biotherapeutics LLC chose not to state its revenue in its newest notice of a funding round (Apr 2024).
SEC Form D · Apr 2024
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2024
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of TORL Biotherapeutics LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Licata | Executive officer | Apr 2024 |
| Mark Alles | Executive officer | Apr 2024 |
| Amit Sinha | Director | Apr 2024 |
| David Licata | Director | Apr 2024 |
| Dennis Slamon | Director | Apr 2024 |
| Lynn Seely | Director | Apr 2024 |
| Mark Alles | Director | Apr 2024 |
| Mark Attanasio | Director | Apr 2024 |
| Neil O'Brien | Director | Apr 2024 |